Compass Therapeutics Inc Ordinary Shares CMPX
News
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment